Production (Stage)
ABVC BioPharma, Inc.
ABVC
$1.15
-$0.06-4.96%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -467.25% | 222.88% | 81.57% | 64.27% | -639.42% |
| Total Depreciation and Amortization | -36.48% | 2,461.43% | -47.37% | -87.02% | -71.48% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 130.45% | -301.27% | -28.74% | -77.52% | 2,890.66% |
| Change in Net Operating Assets | 91.25% | -1,850.79% | 102.57% | -44.71% | 29.06% |
| Cash from Operations | -9.36% | -387.48% | 116.93% | -6.10% | -122.02% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -100.00% | 183.47% |
| Total Debt Repaid | 83.45% | 1.17% | -- | -- | -- |
| Issuance of Common Stock | 439.58% | 126.41% | -96.12% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -100.00% | 433.19% |
| Cash from Financing | -26.26% | 499.93% | -116.74% | -6.02% | 2,306.51% |
| Foreign Exchange rate Adjustments | 11.48% | 662.50% | -99.65% | 978.54% | 84.31% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -210.97% | 246.49% | -67.66% | 244.98% | 85.70% |